IDENTIFYSENSORS RAISES $20 MILLION TO ADVANCE NEW DIGITAL DIAGNOSTICS PLATFORM

CLEVELAND, March 3, 2025 /PRNewswire/ -- IdentifySensors Biologics, a leading developer of digital diagnostic technologies, has raised $20 million to commercialize a software platform using semiconductors that function as rapid biosensors. When connected to a dedicated Bluetooth device, the sensors are intended to rapidly detect targeted gene sequences indicative of infectious diseases and potentially various cancers using a patient sample.

This new platform is intended to redefine molecular detection by eliminating reliance on centralized laboratories, while enabling real-time molecular diagnostics at the point-of-need.

"Current molecular diagnostics are based on decades old technologies that are slow, expensive and require complex laboratories and highly skilled labor to administer," said IdentifySensors CEO Greg Hummer. "This new platform is intended to detect targeted DNA or RNA in minutes through small, simple and inexpensive electronic circuits that interact with Cloud-based algorithms and software."

The sensors are printed with a proprietary ink made from graphene – a single layer of carbon atoms used for advanced electronics, energy storage and health-care applications. The sensors are incorporated into a multiplex test cartridge about the size of a cell phone. The cartridges are designed to analyze a variety of sample types, depending on the target. Each sensor can be programmed to detect and differentiate multiple pathogens or biomarkers simultaneously using a single half milliliter sample, including blood and saliva specimens.

The cartridge connects to a reusable Bluetooth reader. The reader transmits results to a mobile app and cloud-based algorithms, which generate final test results. Users are informed by text message in minutes.

IdentifySensors has started manufacturing and intends to make its first FDA submission later this year. The company's three-year plan includes rapid molecular tests for many common diseases and other conditions, such as cancer that can be molecularly detected through genetic sequences.

IdentifySensors holds more than 20 patents on the technology and manufacturing processes. The company is currently seeking an additional $7.5 million to scale production and develop additional test targets.

About IdentifySensors Biologics
IdentifySensors Biologics is a nano-bio technology company pioneering a paradigm shift in molecular diagnostics from a hardware heavy, laboratory-based delivery model to a low-cost, portable software-based delivery platform. The transition leverages advancements in nanomaterial-based semiconductors, bioinformatics and AI. For more information visit www.identifysensors.com

News Media Contact
Joe Mosbrook
[email protected]
216-375-2141

SOURCE IdentifySensors Biologics